Aurinia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUPH research report →
Range $16 – $18
Price Chart
About the company
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally.
- CEO
- Kevin C. Tang
- IPO
- 2014
- Employees
- 128
- HQ
- Edmonton, AB, CA
Get TickerSpark's AI analysis on AUPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.97B
- P/E
- 6.29
- Fwd P/E
- 15.15
- PEG
- 0.02
- P/S
- 6.20
- P/B
- 3.02
- EV/EBITDA
- 10.26
- Div Yield
- 0.00%
- Gross Margin
- 90.73%
- Op Margin
- 48.60%
- Net Margin
- 97.68%
- ROE
- 51.92%
- ROIC
- 20.91%
Latest fiscal year · YoY change
- Revenue
- $283.06M+20.4%
- Gross Profit
- $250.39M+21.0%
- Op Income
- $104.91M
- Net Income
- $287.20M+4893.1%
- EPS
- $2.14+5250.0%
- OCF Growth
- +205.6%
- FCF Growth
- +207.0%
- 52W High
- $19.25
- 52W Low
- $13.52
- 50D MA
- $16.41
- 200D MA
- $15.74
- Beta
- 1.41
- RSI (14)
- 33
- Avg Volume
- 857.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aurinia delivered another strong year of LUPKYNIS growth in 2025 and raised 2026 sales guidance, while advancing aritinercept and managing a pediatric study termination.· February 26, 2026
- 2025 LUPKYNIS net product sales rose 25% to $271.3 million, with Q4 sales up 29% to $74.2 million.
- Full-year revenue was $283.1 million, up 20% year over year; excluding a prior-year $10 million Japan milestone, revenue was up 26%.
- 2026 guidance calls for total revenue of $315 million to $325 million and LUPKYNIS net product sales of $305 million to $315 million.
- Cash and investments ended 2025 at $398 million, and the company repurchased 12.2 million shares for $98.2 million.
- Management said aritinercept remains on track for more disclosures in Q2 2026, and the pediatric Vocal study was terminated due to recruitment difficulty, with plans to discuss next steps with the FDA.
Fourth-quarter 2025 total revenue was $77.1 million, up 29% from $59.9 million a year ago, and LUPKYNIS net product sales were $74.2 million, up 29% from $57.6 million. Q4 net income was $210.8 million versus $1.4 million last year, reflecting a $175.1 million tax benefit; diluted EPS was $1.53 versus $0.01, and operating cash flow was $45.7 million versus $30.1 million. For full-year 2025, total revenue was $283.1 million, up 20% from $235.1 million, and LUPKYNIS net product sales were $271.3 million, up 25% from $216.2 million; full-year net income was $287.2 million, diluted EPS was $2.07, and operating cash flow was $135.7 million. Cash, cash equivalents, restricted cash and investments were $398 million at December 31, 2025. Guidance for 2026 is total revenue of $315 million to $325 million and net product sales of $305 million to $315 million, both implying low-teens growth versus 2025.
Peter Greenleaf said the commercial strategy for LUPKYNIS is centered on using the product’s efficacy data, longer-term AURORA extension data, biopsy data, and the ACR/ULAR guidelines to push earlier diagnosis and earlier treatment of lupus nephritis. He emphasized that rheumatology is becoming more important, with slightly more of the business now coming from rheumatologists than nephrologists, and said the business is benefiting from more prescriber adoption, better adherence, and persistency. On aritinercept, he described broad excitement about BAFF/APRIL inhibition and said Aurinia is taking a deliberate, methodical approach to selecting indications and rolling out updates.
Joe Miller reported strong operating results, including Q4 revenue of $77.1 million, full-year revenue of $283.1 million, and operating cash flow of $135.7 million for 2025. He highlighted the large tax benefit in both Q4 ($175.1 million) and the full year ($173 million), tied to releasing the valuation allowance on deferred tax assets the company now expects to realize. He also noted the company ended the year with $398 million in cash and investments, repurchased 12.2 million shares for $98.2 million, and reduced fully diluted shares from 149.8 million to 139.7 million.
Analysts focused on why 2026 guidance does not look higher given the fourth-quarter run rate, and management said the outlook reflects historical growth patterns, continued adherence and persistency, payer mix, guideline adoption, and competitive dynamics, while declining to give quarterly steer. Questions on the pediatric Vocal study drew a response that the study was terminated because technical issues made recruitment very difficult, and management said it plans to discuss next steps and pediatric commitments with the FDA. Analysts also pressed on Gazyva and competition; management said it has not seen near-term impact, believes the market is still underpenetrated, and thinks newer competition may help expand diagnosis and treatment overall rather than immediately displace LUPKYNIS.
The call showed continued momentum in LUPKYNIS, with 25% full-year sales growth and management still expecting 12% to 16% net product sales growth in 2026. Management also sounded confident that guideline-driven earlier diagnosis and earlier treatment can expand the market, while aritinercept adds a second pipeline story with more updates expected in Q2 2026.
Management acknowledged competition is increasing, including Gazyva, even if it has not yet seen a near-term impact on the business. The pediatric Vocal study was terminated due to recruitment problems, and Aurinia now has to work with the FDA on how to fulfill pediatric commitments, while aritinercept remains early and details on design and indications are still being withheld. Guidance also suggests growth is expected to moderate from the recent quarter run rate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 134.00M
- Float Shares
- 130.16M
of shares held by institutions
294 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tang Capital Management LLC | 13.04M | ▲ 814.61K |
| Blackrock, Inc. | 8.59M | ▲ 392.29K |
| Goldman Sachs Group Inc | 5.62M | ▲ 4.19M |
| Nea Management Company, LLC | 3.97M | 0 |
| Two Sigma Investments, LP | 3.47M | ▲ 38.81K |
| Arrowstreet Capital, Limited Partnership | 2.98M | ▼ 279.26K |
| State Street Corp | 2.59M | ▲ 2.71K |
| Marshall Wace, Llp | 1.90M | ▼ 146.25K |
| Lsv Asset Management | 1.81M | ▲ 728.26K |
| Morgan Stanley | 1.79M | ▼ 516.27K |
| Geode Capital Management, LLC | 1.72M | ▲ 15.42K |
| Vanguard Group Inc | 1.45M | ▼ 107.63K |
Held by 239 ETFs
Biggest fund positions in AUPH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Robertson Stephen P. | sell | 11,867 |
| Sep 10, 26 | Robertson Stephen P. | sell | 11,939 |
| Aug 21, 26 | Robertson Stephen P. | sell | 20,975 |
| Jun 4, 26 | Johnson Craig A | other | 23,931 |
| Jun 4, 26 | Goetz Kathleen | other | 23,931 |
| Jun 4, 26 | Nova Tina Susan | other | 23,931 |
| Jun 4, 26 | Bailey Jeffrey Allen | other | 23,931 |
| Jun 2, 26 | TANG KEVIN | buy | 206,005 |
| Jun 1, 26 | TANG KEVIN | buy | 99 |
| Jun 1, 26 | TANG KEVIN | buy | 343,521 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AUPH coverage
Recent articles, reports, and earnings notes.
No research on AUPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AUPH report →Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
zacks.com · Oct 30
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
businesswire.com · Oct 30
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
zacks.com · Oct 27
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
zacks.com · Oct 26
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
zacks.com · Oct 23
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)
defenseworld.net · Oct 12
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
zacks.com · Aug 20
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
benzinga.com · Aug 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.